Myriad Genetics, Inc. (NASDAQ: MYGN) announced that it has acquired Sividon Diagnostics, a leading breast cancer prognostic company, for €35 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE